BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant

BioAffinity Technologies Inc. (NASDAQ: BIAF) experienced a significant stock surge of 50.47%, reaching $8.05, following the grant of a key patent in Hong Kong for its CyPath Lung diagnostic. This patent complements an existing patent in China, providing dual intellectual property protection in a region with a high incidence of lung cancer. The CyPath Lung diagnostic has shown robust clinical performance with a 92% sensitivity and is now protected in multiple regions including the U.S., Europe, and Japan.